MX2023002589A - Derivados de fumagilol y polimorfos de los mismos. - Google Patents

Derivados de fumagilol y polimorfos de los mismos.

Info

Publication number
MX2023002589A
MX2023002589A MX2023002589A MX2023002589A MX2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A
Authority
MX
Mexico
Prior art keywords
polymorphs
fumagillol derivatives
fumagill
aminocyclohexyl
trans
Prior art date
Application number
MX2023002589A
Other languages
English (en)
Inventor
John S Petersen
Original Assignee
Syndevrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndevrx Inc filed Critical Syndevrx Inc
Publication of MX2023002589A publication Critical patent/MX2023002589A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C07C309/26—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a sales y polimorfos de carbamatos de aminoalquilfumagilol (por ejemplo, sal de ácido bencenosulfónico de N-(trans-4-aminociclohexil)carbamato de fumagil-6-ilo y sal de ácido hidroxinaftoico de N-(trans-4-aminociclohexil)carbamato de fumagil-6-ilo). Los polimorfos se caracterizan por difracción de polvo de rayos X, calorimetría de exploración diferencial y análisis termogravimétrico, entre otros métodos. Los polimorfos y sales pueden usarse como intermediarios en la producción de derivados de fumagilol (por ejemplo, derivados de fumagilol conjugados con polímero) así como agentes terapéuticos para el tratamiento de varias enfermedades y condiciones tales como cáncer.
MX2023002589A 2015-12-10 2018-06-06 Derivados de fumagilol y polimorfos de los mismos. MX2023002589A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265675P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
MX2023002589A true MX2023002589A (es) 2023-03-22

Family

ID=57589276

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018006904A MX2018006904A (es) 2015-12-10 2016-12-09 Derivados de fumagilol y polimorfos de los mismos.
MX2023002589A MX2023002589A (es) 2015-12-10 2018-06-06 Derivados de fumagilol y polimorfos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018006904A MX2018006904A (es) 2015-12-10 2016-12-09 Derivados de fumagilol y polimorfos de los mismos.

Country Status (12)

Country Link
US (2) US9969722B2 (es)
EP (1) EP3386956B1 (es)
JP (2) JP7553224B2 (es)
KR (1) KR20180093995A (es)
CN (1) CN108290853B (es)
AU (1) AU2016366306B2 (es)
CA (1) CA3005450A1 (es)
DK (1) DK3386956T3 (es)
ES (1) ES2893749T3 (es)
HK (1) HK1258254A1 (es)
MX (2) MX2018006904A (es)
WO (1) WO2017100553A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
ES2749746T3 (es) 2013-04-10 2020-03-23 Syndevrx Inc Inhibidores de fumagilol metap2 modificados o conjugados con polímeros para uso en el tratamiento de la obesidad
CN114225045A (zh) 2016-01-11 2022-03-25 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
EP3870231A1 (en) 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
WO2024040009A2 (en) * 2022-08-17 2024-02-22 Primetime Life Sciences, Llc Inhibitors of methionine aminopeptidase-2 and methods of preparation and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US4997878A (en) 1988-12-29 1991-03-05 Exxon Research And Engineering Company Hydrophobically associating polymers containing dimethyl acrylamide functionality
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
AU9376998A (en) 1997-09-02 1999-03-22 Johns Hopkins University School Of Medicine, The Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
ATE269699T1 (de) 1997-10-31 2004-07-15 Childrens Medical Center Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
CA2333321A1 (en) 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Drug complex
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
AU765409B2 (en) 1998-10-30 2003-09-18 Daiichi Pharmaceutical Co., Ltd. DDS compounds and method for assaying the same
WO2001018080A1 (en) 1999-09-08 2001-03-15 School Of Pharmacy, University Of London Uniform molecular weight polymers
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20070161570A1 (en) 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
DE60233420D1 (de) 2001-09-27 2009-10-01 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
US20040005641A1 (en) 2002-02-15 2004-01-08 Michael Burnet Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2003086382A1 (en) 2002-04-11 2003-10-23 Children's Medical Center Corporation Tnp-470 polymer conjugates and use thereof
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US20040116348A1 (en) 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US20040228831A1 (en) 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
CN1922332B (zh) 2003-12-31 2013-06-12 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US7214664B2 (en) 2004-12-03 2007-05-08 The Curators Of The University Of Missouri Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
US20080248030A1 (en) 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2006124711A1 (en) 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
CA2690244C (en) 2007-06-26 2016-08-09 Ofra Benny-Ratsaby Metap-2 inhibitor polymersomes for therapeutic administration
WO2009036108A1 (en) 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
US8399512B2 (en) 2007-11-28 2013-03-19 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
WO2009087664A1 (en) 2007-12-04 2009-07-16 Cadila Healthcare Limited Process for preparing chemically and chirally pure solifenacin base and its salts
EP2244712B1 (en) 2008-01-22 2015-08-05 Thar Pharmaceuticals Inc. In vivo studies of crystalline forms of meloxicam
EP2307032A4 (en) 2008-05-22 2014-08-20 Univ Ramot NOVEL POLYMER CONJUGATES HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS-TARGETING FRACTION AND USES THEREOF FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
TWI373345B (en) 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital INHIBITION OF NOTCH FOR THE TREATMENT AND PREVENTION OF OBESITY AND METABOLIC SYNDROME
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US20130137831A1 (en) 2010-05-25 2013-05-30 John S. Petersen Optimized drug conjugates
UA111479C2 (uk) 2010-11-09 2016-05-10 Зафджен, Інк. Кристалічні форми інгібітору metap-2 та способи їх отримання і застосування
WO2012122264A1 (en) 2011-03-08 2012-09-13 Zafgen Corporation Oxaspiro [2.5] octane derivatives and analogs
WO2013169860A1 (en) * 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
ES2749746T3 (es) 2013-04-10 2020-03-23 Syndevrx Inc Inhibidores de fumagilol metap2 modificados o conjugados con polímeros para uso en el tratamiento de la obesidad
CN114225045A (zh) 2016-01-11 2022-03-25 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗

Also Published As

Publication number Publication date
JP2019501898A (ja) 2019-01-24
CN108290853A (zh) 2018-07-17
JP2024103495A (ja) 2024-08-01
CN108290853B (zh) 2022-05-31
US20180291010A1 (en) 2018-10-11
DK3386956T3 (da) 2021-10-11
JP7553224B2 (ja) 2024-09-18
KR20180093995A (ko) 2018-08-22
US10287277B2 (en) 2019-05-14
ES2893749T3 (es) 2022-02-10
US20170166556A1 (en) 2017-06-15
CA3005450A1 (en) 2017-06-15
EP3386956B1 (en) 2021-07-14
AU2016366306A1 (en) 2018-05-31
HK1258254A1 (zh) 2019-11-08
WO2017100553A1 (en) 2017-06-15
AU2016366306B2 (en) 2021-02-25
EP3386956A1 (en) 2018-10-17
US9969722B2 (en) 2018-05-15
MX2018006904A (es) 2018-08-24

Similar Documents

Publication Publication Date Title
MX2023002589A (es) Derivados de fumagilol y polimorfos de los mismos.
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CY1119731T1 (el) Διαδικασια για την παρασκευη παραγωγων χολικου οξεος
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
MX2021014128A (es) Polimorfos de selinexor.
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201691629A1 (ru) Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
WO2014152389A8 (en) Imaging agent for detection of diseased cells
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
PH12014502141A1 (en) New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
CY1121137T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν ανταγωνιστες ccr3
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
EA201592144A1 (ru) Производное фенола, способ его получения и его применение в медицине
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201691141A1 (ru) Соединения против ccr6
MY160785A (en) Manufacturing process for pyrimidine derivatives
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
CL2020001589A1 (es) Proceso para la preparación de derivados de quinolina.
EA201891023A1 (ru) Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции
AU2018341781A8 (en) Fused ring derivative as A2A receptor inhibitor
CY1124838T1 (el) Αλας παραγωγου κεφαλοσπορινης, κρυσταλλικη, στερεη μορφη αυτου και μεθοδος παραγωγης αυτου